Table 3. Theoretical vaccine coverage.^a .

Vaccine coverage	Total sampleb	Death	Non-death	p
	(N = 118)	(n = 39)	(n = 77)
PCV13 alonec	1 (0.8)	1 (2.6)	0 (0.0)
PPV23 aloned	37 (31.4)	12 (30.8)	25 (32.5)	0.508
PCV13 plus PPV23	60 (50.8)	19 (48.7)	41 (53.2)
No coverage	20 (16.9)	7 (17.9)	11 (14.3)

PCV13: 13-valent pneumococcal conjugate vaccine; and PPV23: 23-valent pneumococcal polysaccharide vaccine (PPV23). ^aValues expressed as n (%). ^bTwo patients with unknown outcome status (no vaccine coverage). ^cSerotype 6A. ^dSerotypes 3, 8, 9N, 10A, 11A, 12F, 15B, 17F, 20, 22F, and 33F.